Giles Platford/LinkedIn
Dec 12, 2025, 09:34
Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, shared on LinkedIn:
”Plasma-derived therapies are often the only effective treatment for patients with certain rare and complex, chronic conditions.
One case in point is infant botulism: in partnership with the California Department of Public Health, on a non-profit basis, Takeda produces the only FDA-approved treatment for this condition, Baby Big.
The recent outbreak of infant botulism in the U.S. has put a fine point on the importance of this therapy.
Learn more in this story from The Independent”
Stay updated with Hemostasis Today.
-
Apr 26, 2026, 13:48Jecko Thachil։ How to Anticoagulate Patients with Thrombocytopenia and Thrombosis
-
Apr 26, 2026, 13:47Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab
-
Apr 26, 2026, 13:41Ayesha Saleem: Bridging the Gap Between Awareness and Diagnosis of vWD in Pakistan
-
Apr 26, 2026, 13:20Tasawar Siddique: Early Detection of Nephrotic Syndrome
-
Apr 26, 2026, 12:51Michael Stark: Join the Discussion on Cord Blood vs Adult Blood
-
Apr 26, 2026, 12:21Alex John London: AI in Healthcare Must Show Safety and Efficacy Before Use
-
Apr 26, 2026, 12:01David McIntosh: Raising Awareness on the Worldwide Shortage of Plasma-Derived Medicines
-
Apr 26, 2026, 12:00José Antonio García Erce: Where Is the Limit in Blood Donation Age?
-
Apr 26, 2026, 11:59Tomas Holubec: A New Chapter in Cardiac Surgery in Nuremberg